Cost-Analysis of the Different Treatment Modalities in X-Linked Dystonia–Parkinsonism
Background: X-linked dystonia-parkinsonism (XDP) is a debilitating disease endemic in the Philippines. Several oral medications as well as botulinum toxin A (BoNT-A) injection and deep brain stimulation (DBS) surgery appear to be the cornerstone of treatment in XDP, which are commonly used in combin...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2019-05-01
|
| Series: | Frontiers in Neurology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fneur.2019.00500/full |
| _version_ | 1811240321476984832 |
|---|---|
| author | Ranhel C. De Roxas Roland Dominic G. Jamora Roland Dominic G. Jamora |
| author_facet | Ranhel C. De Roxas Roland Dominic G. Jamora Roland Dominic G. Jamora |
| author_sort | Ranhel C. De Roxas |
| collection | DOAJ |
| description | Background: X-linked dystonia-parkinsonism (XDP) is a debilitating disease endemic in the Philippines. Several oral medications as well as botulinum toxin A (BoNT-A) injection and deep brain stimulation (DBS) surgery appear to be the cornerstone of treatment in XDP, which are commonly used in combination. Being a chronic progressive disease, it is an economic burden to the patient and their families. Thus, we aim to perform a comparative analysis of the associated healthcare costs for the therapeutic options used in XDP.Methodology: A questionnaire assessing the healthcare costs in the management of XDP was designed and administered through an interview with the XDP patients or their caregivers. We analyzed the data and a bootstrap analysis was also done to obtain a more generalizable estimation of the costs.Results: A total of 110 gene-positive XDP patients were included in this study. The mean total annual cost per patient was USD 4,861.23 (USD:PHP 1:50, as of January 8, 2018). More than half of the patients (n = 61, 55.5%) received both oral medications and BoNT-A injection while 42 patients (38.2%) received oral medications alone. Only seven patients underwent DBS with a reported estimated cost of USD 50,931.43. The bootstrap analysis confirmed the estimates done in this study.Conclusion: The estimated costs in the management of XDP was shown to be 30 times the average annual health expenditure of an average Filipino. This calls for more government effort to provide comprehensive care for chronic and debilitating diseases such as XDP. |
| first_indexed | 2024-04-12T13:18:09Z |
| format | Article |
| id | doaj.art-249d49f3694c44ec9f5a706cb51776df |
| institution | Directory Open Access Journal |
| issn | 1664-2295 |
| language | English |
| last_indexed | 2024-04-12T13:18:09Z |
| publishDate | 2019-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Neurology |
| spelling | doaj.art-249d49f3694c44ec9f5a706cb51776df2022-12-22T03:31:37ZengFrontiers Media S.A.Frontiers in Neurology1664-22952019-05-011010.3389/fneur.2019.00500459166Cost-Analysis of the Different Treatment Modalities in X-Linked Dystonia–ParkinsonismRanhel C. De Roxas0Roland Dominic G. Jamora1Roland Dominic G. Jamora2Department of Neurosciences, Philippine General Hospital, University of the Philippines Manila, Manila, PhilippinesDepartment of Neurosciences, College of Medicine – Philippine General Hospital, University of the Philippines Manila, Manila, PhilippinesMovement Disorders Service, Institute for Neurosciences, St. Luke's Medical Center, Quezon City, PhilippinesBackground: X-linked dystonia-parkinsonism (XDP) is a debilitating disease endemic in the Philippines. Several oral medications as well as botulinum toxin A (BoNT-A) injection and deep brain stimulation (DBS) surgery appear to be the cornerstone of treatment in XDP, which are commonly used in combination. Being a chronic progressive disease, it is an economic burden to the patient and their families. Thus, we aim to perform a comparative analysis of the associated healthcare costs for the therapeutic options used in XDP.Methodology: A questionnaire assessing the healthcare costs in the management of XDP was designed and administered through an interview with the XDP patients or their caregivers. We analyzed the data and a bootstrap analysis was also done to obtain a more generalizable estimation of the costs.Results: A total of 110 gene-positive XDP patients were included in this study. The mean total annual cost per patient was USD 4,861.23 (USD:PHP 1:50, as of January 8, 2018). More than half of the patients (n = 61, 55.5%) received both oral medications and BoNT-A injection while 42 patients (38.2%) received oral medications alone. Only seven patients underwent DBS with a reported estimated cost of USD 50,931.43. The bootstrap analysis confirmed the estimates done in this study.Conclusion: The estimated costs in the management of XDP was shown to be 30 times the average annual health expenditure of an average Filipino. This calls for more government effort to provide comprehensive care for chronic and debilitating diseases such as XDP.https://www.frontiersin.org/article/10.3389/fneur.2019.00500/fullcost analysisdystoniaparkinsonismXDPhealthcare costlubag |
| spellingShingle | Ranhel C. De Roxas Roland Dominic G. Jamora Roland Dominic G. Jamora Cost-Analysis of the Different Treatment Modalities in X-Linked Dystonia–Parkinsonism Frontiers in Neurology cost analysis dystonia parkinsonism XDP healthcare cost lubag |
| title | Cost-Analysis of the Different Treatment Modalities in X-Linked Dystonia–Parkinsonism |
| title_full | Cost-Analysis of the Different Treatment Modalities in X-Linked Dystonia–Parkinsonism |
| title_fullStr | Cost-Analysis of the Different Treatment Modalities in X-Linked Dystonia–Parkinsonism |
| title_full_unstemmed | Cost-Analysis of the Different Treatment Modalities in X-Linked Dystonia–Parkinsonism |
| title_short | Cost-Analysis of the Different Treatment Modalities in X-Linked Dystonia–Parkinsonism |
| title_sort | cost analysis of the different treatment modalities in x linked dystonia parkinsonism |
| topic | cost analysis dystonia parkinsonism XDP healthcare cost lubag |
| url | https://www.frontiersin.org/article/10.3389/fneur.2019.00500/full |
| work_keys_str_mv | AT ranhelcderoxas costanalysisofthedifferenttreatmentmodalitiesinxlinkeddystoniaparkinsonism AT rolanddominicgjamora costanalysisofthedifferenttreatmentmodalitiesinxlinkeddystoniaparkinsonism AT rolanddominicgjamora costanalysisofthedifferenttreatmentmodalitiesinxlinkeddystoniaparkinsonism |